Panel endorses Eli Lilly's new Alzheimer's drug donanemab - McKnight's Long-Term Care News

An independent advisory panel to the US Food and Drug Administration on Monday gave the green light to Eli Lilly's experimental Alzheimer's drug donanemab. The FDA should vote on approval later this year, STAT reported.

Related Keywords

,Jim Taylor ,Joshua Cahan ,Eli Lilly ,Drug Administration On ,Reuters ,Northwestern University Feinberg School Of Medicine ,Getty Images ,Drug Administration ,Northwestern University Feinberg School ,